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Clinical evaluation of a CAPD program. (November 1981—December
1985). V. Vargemezis, 0. Liamos, V. Kilintzis, R. Antoniadou, Chr.
Hatzidimitriou, K. Meiska, E. Psarra, and M. Papadimitriou, 2nd
Prop. Dept. of Medicine, Aristotelian University Thessaloniki, Greece.
Since November 1981, 145 patients (78 male) with a mean age of 51
years (range eight to 85 years) have been treated by continuous
ambulatory peritoneal dialysis for a total of 2338 patient—months.
Seventy—three patients (50.3%) were between 40 to 60 years old, 40
patients (27.5%) were >60 years old and 32 patients (22.2%) were <40
years old. The primary renal disease in 32 patients (38.6%) was chronic
glomerulonephritis, 27 patients (17.2%) had diabetic nephropathy, 21
patients (14.5%) chronic pyelonephritis, 17 patients (11.7%) polycystic
disease, 9 (6.2%) malignant nephrosclerosis, four obstructive nephrop-
athy, three malignant disease, three amyloidosis, two vasculitis, two
oxalosis, and one uremic hemolytis syndrome. The mean follow—up of
these patients was 16 10 months (range 2 to 40 months). During this
period there were 189 episodes of peritonitis with and incidence of one
episode per 12.4 patient—months. Fifteen patients of our population
(10.3%) were transferred to HD programme, nine patients (6.2%) were
transplanted and 27 patients (18.6%) died. In our experience, continu-
ous ambulatory peritoneal dialysis (CAPD) is considered as a feasible
alternative mode of treatment in patients with end—stage renal disease.
However, the clinical experience showed that the CAPD program is
overloaded with many problematic patients, such as diabetics or elders
who are inappropriate for artificial kidney or renal transplantation.
Continuous ambulatory peritoneal dialysis (CAPD) in Greece. A.
Agrafiotis, A. Katirtzoglou, G. Papadakis, V. Vergemezis. N. Dom-
bros, Hospitals: Laiko, Ippokratio, Evangelismos—A thens, Ag. Sofia,
AHEPA—Salonika, Greece. In Greece, since the 31st October 1982
until the 31st October 1985, 286 patients (158 males, 128 females) 18 to
82—years—old were treated with CAPD. In 180 cases, CAPD was the
initial form of treatment. The Tenckhoff type of catheter was used in
178 cases and the TW-H in 108. General anesthesia was used in 74,
while local anesthesia in 212 cases. Two hundred and eleven patients
have used peritoneal dialysate containing acetate, while 75 of them used
lactate dialysates. During CAPD treatment the need for increase of the
number of hypertonic dialysate (4% glucose) evolved in 25% of all
cases. Clinico-laboratory control was done every 30 to 60 days, and the
connector was changed every 12 days to five months. Dialysate leakage
(18%), exit site infection (5%) and functional failure of the catheter (4%)
were early complications. Late complications were backache (20%),
hernias(19%), dialysate leakage (8%), ischemia of the lower extremities
(6%), hemorrhoids (6%), and one way catheter obstruction (3%). There
were 337 cases of peritonitis (1/13 months). In 64% of them Gram (+)
bacteria was identified. Fungal peritonitis was 10% of all cases of
peritonitis. Of the 286 patients, 29 were transferred to hemodialysis
(59% due to peritonitis). 10 patients were submitted to renal transplan-
tation. 58 deaths occurred (59% due to cerebrovascular accidents). 189
patients are still on CAPD (66% of the total number during the 3-years
period). Full recovery was noted in 72% of the cases, while partial
recovery in 13% of them. The 1st cumulative results of CAPD in Greece
are comparable to those of other countries & are encouraging for future
development of this method in our country.
A comparative prospective study of titanium adapter (TA) and luer-
lock plastic adapter (PA) in CAPD. A. Katirtzoglou, K. Platsakis, N.
Apostolidis, B. Pararas, TH. Mountokalakis, 2nd Department of Inter-
nal Medicine, Athens University Medical School, Hippokration Hospi-
tal, Athens, Greece. It has been proposed that TA is preferable to PA
because of the spontaneous disconnections from the tubing set and
other problems related to the later. In a prospective study we compared
the use of TA and PA for a period of three years. During this period TA
or PA were alternatively applied to 39 patients. Twenty patients with
TA formed group A and 19 patients with PA group B. Throughout the
study the training technique and the nursing staff were kept the same.
The total duration on CAPD was 370 and 366 patient months, respec-
tively, in each group. Seventeen episodes of peritonitis occurred in each
group, that is one episode every 21.7 and 21.5 patient months, respec-
tively. Responsible organisms were staph, epidermidis in 8 and 9 cases,
respectively, and gram—negative bacteria in 3 cases in each group. The
number of the hospital days per patient was similar in both groups (18.9
and 18.8, respectively). Furthermore, total mortality did not differ
between the two groups (6/20 in group A and 5/19 in group B). It is
noteworthy that no disconnections or cracks of the adapter occurred in
the PA group. Due to loss of elasticity of the peritoneal catheter over
adapter nozzle TA had to be replaced in two patients. The above results
indicate that both PA and TA are equally safe against accidental
catheter separation. Therefore, there is no reason to quit PA which has
the additional advantage of being less expensive.
latrogenic or not, uncommon complications of CAPD. S. Ant oniou, A.
Di,nitriadis, G. Lakassas, Ch. Kamidon, A. Pavlitou, and D. Stama-
topoulou, 1st Dept. mt. Med., 'AG.DIMITRIOS" Hasp. Thessaloniki,
Greece. Patients on CAPD often present complications such as leakage.
peritonitis, etc. However there are some rare complications with very
discussable pathogenesis attributed to the procedure of CAPD as well
as to related medical interventions. Among 21 patients followed for 198
mo-pat we observed the following uncommon complications: a) Histi-
ocytic infiltration of bone marrow and lymph nodes in a woman, 60
years—old, with very high hyperlipidemia and severe anemia. b) "Re-
jection" of the catheter with generalised hypersensitivity reaction with
heosinophilia. c) Persistent symptoms from joints and gut, attributed to
infection from Yersinia enterocolitica. d) A case of toxic hepatitis and
thrombocytopenia from drugs and two cases of severe drug ototoxicity.
e) Unusual infections such as severe bronchopneumonia from entero-
bacter and serratia and a severe mycotic peritonitis with damage of
peritoneum and viscera. f) Partial resection of epiploon for vaste
adhesions in a patient with sclerosing peritonitis. In conclusion, it
seems that exists a constellation of rare complications of CAPD, that
could be caracterised 'iatrogenic" and for which the frequency has to
be proved and the severity kept in mind.
Fungal peritonitis (FP) in CAPD. The importance of peritoneal catheter
(CT). A. Agrafiotis, A. Katirt zag/au, K. Platsakis, J. Boletis, M. Tjivra.
Th. Mountokalakis, Laikon General Hospital Department of Nephrol-
ogy and 2nd Department of Internal Medicine, Athens University
Medical School, Hippokration Hospital, Athens, Greece. FP in CAPD
is considered to be a hard to solve problem usually imposing CT
removal. In 77 CAPD patients (46 males, 31 females) with a total of 1549
months in CAPD we had 56 cases of peritonitis (1/18 months) from
which 8 were FP. FP usually followed bacterial peritonitis under
treatment. In 3 cases fungal focuses of the skin and/or mucosa were
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identified. In one case, 5-day lavage with amphotericin-B (2 mg/liter)
was used in association with 50 day treatment with oral Ketokonazole
and 5-fluocytocine. Although dialysate cultures were negative since the
first day of treatment, there was a relapse 2.5 months later which led to
CT removal. In the following 3 cases the same regiment was used and
CT was removed after 3 succesive negative dialysate cultures. In the
next 3 cases CT was removed immediately after diagnosis and no
specific treatment was instituted. The last case was treated with
intraperitoneal Miconazole, 2 months p.os Ketokonazole and CT dis-
infection with Betadine solution, while the patient remained on CAPD.
No relapse occurred 7 months after treatment. There was no deaths
from FP in the above 8 cases; one patient died from acute myocardial
infarction. Our observations suggest that in FP, CT should be the prime
target of treatment, either by removal or by sterilization, the later
associated with obvious advantages.
Peritoneal kinetics of iron dextran during peritoneal dialysis in the
rabbit—electron microscopic study. G.F. Digenis, S. Rabinovich, A.
Medline, H. Rode/la, G. Wu, D.G. Oreopoulos, Pathology Department
of Toronto Western Hospital and 2nd Department of Internal Medicine,
Athens University Medical School, Athens, Greece. In order to study
the peritoneal kinetics of iron dextran, an intravenous injection of this
electron dense tracer was given (100 mg/l00 g of body weight) in 8
normal rabbits during peritoneal dialysis. The dialysate contained 1.5
g/dl of glucose in 4 animals and 4.25 g/dl in the remainder. Peritoneal
dialysis discontinued and the peritoneum was fixed in vivo at various
times (20—120 mm) after the injection of iron dextran. Electron micro-
scopic examination of the mesentery showed particles of iron dextran in
the endothelial cells of small vessels (capillaries and venules) the
interstitium and the mesothelial cells adjacent to vessels irrespective of
the kind of dialysate or the duration of dialysis. Tracer was not clearly
demonstrated in the interendothelial or intermesothelial spaces. In the
mesothelial cells, the particles were found exclusively in (small, large or
elongated) vesicles while in the endothelial cells they were both in
vesicles and free in the cytoplasm. These findings suggest that during
the 20 to 120 mm period after intravenous administration, the intracel-
lular transport of iron dextran depends on either moving vesicles or the
presence of preexisting tunnels in the mesothelial cells of rabbit
mesentery.
The effect of CAPD on cellulal immunity in vivo and in vitro study. A.
Agrafiotis, A. Stavropoulou, M. Papanikolaou, D. Stamatiadis, E.
Dafnis, S. Michael, Laiko Hospital Department of Nephrology, Gen-
eral Hospital Histocompatibility Laboratory, Athens, Greece. For the
evaluation of cellular immunity of CAPD patients, the E-Rosette
technique (E-R) was performed with blood samples drawn from 10
CAPD patients at the commencement of treatment, 6 and 12 months
later, and from 12 hemodialysis (HD) patients who had been on
treatment for 13 4 months. CAPD patients showed E-R percentage
within normal limits (80 14) and statistically significantly (P < 0.01)
higher than before treatment. HD patients showed significantly (P <
0.01) lower E-R values (62 5). T-lymphocytes from healthy controls'
blood were incubated in peritoneal dialysate (PD) and this produced
significant drop of E-R formation, something which did not occur with
HD dialysate. PD treatment with chloroform reversed the dialysates
E-R suspension, while a 4 hour dialysis of the PD would not produce the
same effect. This shows that the responsible substance is lipoidic. PD
was seperated into a fraction of MW < 5000 andanother of MW > 5000
by recycled ultrafiltration (cellulose membrane). Maximum E-R inhibi-
tion was produced by the <5000 fraction. We conclude that CAPD
improves cellular immunity of renal patients by clearing lipoidic toxin(s)
ofMW <5000.
CAPD and hemodialysis (HD) effect on renal patient cellular immunity.
A. Agrafiotis, A. Stavropoulou, M. Papanikolaou, S. Michael, D.
Stamatiadis, I. Alexopoulos, Department of Nephrology, Laiko Hos-
pital, Histocompatibility Laboratory General Hospital, Athens,
Greece. The effect of dialysis therapy on renal patient's cellular
immunity was studied in 8 CAPD, 12 HD patients and 12 healthy
controls with the use of OKT monoclonal antibodies (ORTHO), in
which T3 antibodies are used for the assesment of the total T-lymph-
ocyte count, T4 for the 'helper' and T8 for the 'suppressor—killer' cells
estimations. Blood samples were drawn from the CAPD patients at the
initiation of treatment and 6 and 12 months after. HD patients' samples
were taken at times t1 and t, which were 6 months apart. In HD patients
we found both the number of helper T-cells and the helper/suppressor
ratio to be significantly lower than in the CAPD and control groups. No
difference, regarding the above two parameters, was found between the
later two groups, after 12 months ofCA PD treatment. We conclude that
CAPD improves renal patient's cellular immunity in contrast to HD
treatment.
In vitro study of T-Iymphocyte transformation in CAPD and
hemodialysis (HD) patients. A. Agrafiotis, A. Stavropoulou, D. Stama-
tiadis, G. Metaxatos, I. Kyriasis, M. Papanikolaou, Department of
Nerhrology, Laiko Hospital, Histocompatibility Laboratory General
Hospital, Athens, Greece. T-Lymphocyte transformation and methyl-
prednisolone suppressive effect were studied in vitro for 8 CAPD
patients 8 HD patients and 8 healthy controls, the three groups being
homogeneous with regard to sex, age and time on dialysis. After
T-Lymphocyte isolation with E-Rosette technique and PHA stimulation
the cells were incubated with C'4-thymidine, without and with the
presence of methylprednisolone in various concentrations. The degree
of lymphocyte transformation and the suppressive effect of methylpred-
nisolone on the proliferative response of the cells, were estimated by
the degree of thymidine absorption (cpm). CAPD patients showed no
difference to controls regarding both T-cell transformation and resist-
ance to methylprednisolone suppression, while HD patients had both
significantly lower (P < 0.01). We conclude that CAPD patients have a
better cellular immunity than HD patients.
Subpopulations of lymphocytes and monocytes in the peripheral blood
of patients with end—stage renal disease. A. Psarra, H. Choremi, M.
Siakotos, A. Kofina, G.R. Vosnides, A.G. Billis, J. Economidou,
Immunology Department and Renal Department of Evangelismos
Hospital, Athens, Greece. Uremia is associated with impairment of the
immune function, but its exact nature and mechanism remains un-
known. Peripheral blood lymphocyte subpopulations (T11+, T3+,
T4+, T8+, Smlg+) and monocytes (Iatex+, Mol+, Mo2+) were
studied by indirect immunofluorescence using monoclonal antibodies
in: a) 9 uremic patients with renal failure in the preterminal phase (PTP),
b) 12 uremic patients on hemodialysis (HD), c) 29 uremic patients on
hemodialysis who had received blood transfusions (HD+TR), d) 15
normal controls. The results (mean SD) were as follows:
Thus: a) PTP patients have significant decrease in the absolute numbers
Group
Lymph/
mm3
T3/
mm3
T4/
mm3
T8/
mm3 Latex+% Mol% Mo2%
A. PTP 1059b 750b 498b 304b 389b13.7
462b
14.0
26.9
25.3
B.HD 1815°
1372° 895° 477 33.0° ND ND
C. HD+TR 1985" 1473" 1007° 574° 38•9b ND ND
D. Con-
2165 1629 1070 548 l9.4 20.0 16.2
trols ±762 ±566 ±407 ±206 ±5.2 ±7.7 ±8.5
of lymphocyte subpopulations without significant alterations in their
percentages, while in the other two groups of patients no significant
difference was observed compared to the controls. b) Duration of HD or
number of transfusions did not affect the absolute numbers or the
percentages of lymphocyte subpopulations. c) In all groups of uremic
patients a highly significant increase in the percentage of macrophages
(latex+) was observed, which in PTP patients was found to belong to
the monocyte/macrophage series.
a p < 0.01
b p < 0.001
A,B,C vs. D P < 0.01 B,C, vs. A
"P <0.001
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Ceftazidime (CAZ) pharmacokinetics in chronic renal failure (CRF)
patients. P. Nikolaidis, A. Tourkantonis, First Department of Internal
Medicine, University of Thessaloniki, Greece. CAZ is a new third
generation cephalosporin with high activity against Pseudomonas aeru-
ginosa. Fifteen patients and eight controls were including in the
pharmacokinetic study. Patients were divided into three groups accord-
ing to their creatinine serum (Crs). Five patients with Crs 1.2 to 3 mg%
(Group A), six patients with Crs 3.1 to 8 mg% (Group B) and four
patients with Crs > 8 mg% (Group C). One g CAZ was administered i.v.
and CAZ serum and urine levels were determined at various times after
administration. The serum and urine levels of CAZ were measured by
microbiological technique. Pharmacokinetic analysis was performed
using the two compartment open model. The pharmacokinetic param-
eters of CAZ are summarised in the following table (mean).
Group *Tl/2 AUC K CLt CLr FU
Control 1.9 175.0 0.365 100.5 81.7 80.1
Group A 7.5 775.3 0.104 31.5 20.4 58.5
Group B 12.2 1132.8 0.058 17.0 4.8 28.2
Group C 19.0 1413.2 0.036 11.6 2.3 19.8
* Tl/2 = elimination half life (h), AUC = area under curve (mg/l,h),
K = elimination rate constant (h), CLt = total body clearance
(mllmin), CLr = renal clearance (mI/mm), FU = urinary recovery (%).
The mean Tl/2 and AUC were increased in relation to the degree of
CRF while the K, CLt, CLr and FU were degreased with redused renal
function. Our pharmacokinetic data suggest that in patients with CRF
dosage adjustment according to the renal function might be necessary.
Pharmakokinetic of zinc in chronic renal failure. D. Grekas, P.
Nikolaides, P. Alexiou, A. Tourkantonis, First Medical Department,
University Hospital AHEPA, Thessaloniki, Greece. Metabolism of zinc
and its pharmakokinetic behavior in chronic renal failure (CRF) are not
yet known. 12 patients with CRF and 6 patients on hemodialysis (HD)
were included in the study. The results were compared with those of 6
healthy controls. After overnight fasting all studied groups were given
i.v. 133 mg of elemental zinc as zinc chloride. Blood samples were
drawn at 0, 10, 20, 30, 60, 120, 240 minutes and 8 hours after zinc
administration. Plasma zinc was measured by atomic absorption spec-
trophotometry (Perkin—Elmer 306A). Basal plasma zinc levels were
0.86 g/ml, 0.65 g/ml and 0.92 g/ml for controls, CRF and HD
patients respectively. Maximal plasma zinc levels observed 10 mm after
zinc administration were 2.54 zg/ml, 2.77 .tg/ml and 3.70 ig/ml,
respectively. T'/2 and volume distribution of zinc showed differentiation
between studied groups, but it was significantly different (P < 0.05) only
between controls and HD patients. Elimination rate (Kel) and AUC
(area under curve) were found to have no significant difference between
groups, while zinc clearance was significantly different (P < 0.05)
between both groups of patients and controls. Conclusion: zinc metab-
olism was found increased in both CRF and HD patients and it may be
probably due to compensatory intestinal zinc excretion.
HLA-A, B, DR antigens in Greek patients with idiopathic glomerulo-
nephritis. C. Pachoula—Papasteriades, P. Arseni, G. Vosnides, F.
Sotsiou, M. Varla, TH. Theodorides, A. Billis, J. Economidou, Dpts of
Immunology and Nephro!ogy, 'Evangelismos" Hospital, Athens
Greece. The aim of this study was to investigate the distribution of
HLA-A, B, DR antigens in Greek patients with idiopathic glomerulo-
nephritis (IGN). One hundred—twenty—one patients with biopsy proven
IGN were tested (82 male and 39 female, aged 15—68 years).
Forty—seven had proliferative GN (PGN), 64 non-PGN and 10 unclas-
sified GN. Thirty—eight patients had idiopathic membranous glomeru-
lonephritis (IMGN). All patients and 380 controls were tested for
HLA-A,B antigens in a microlymphocytotoxic test. HLA-DR typing
was performed on B lymphocytes (separated from T lymphocytes by
AET rosettes) in a microlymphocytotoxicity assay with prolonged
incubation times. Fifty—five patients (27 of them with IMGN) and 90
controls were also typed for HLA-DR. The observed differencies in the
frequency of HLA antigens in the groups studied, are listed below:
Patients
Con-
trols IGN PGN NPGN I
HLA % % P % p % p %
MGN
p
B8 8.9 18.1 <0.01 13.1 N.S. 22.0 <0.01 28.9 <0.001
DR3 27.7 41.8 N.S. 13.0 N.S, 61.2 <0.01 62.9 <0.01
These findings indicate that I) HLA genes or genes closely linked to this
region are involved in the pathogenesis of IMGN in Greek patients. 2)
The genetic background of non-PGN is different from that of PGN.
Estimation of circulating immunocomplexes (CI) on patients with
idiopathic and secondary glomerulopathies. G. Sakellariou, E. Pashali-
dou, M. Papadimitriou, Second Dept of Internal Medicine, Agia
Sophia Hospital, Aristotelion University of Thessaloniki, Greece. The
circulating immunocomplexes (Cl) are important pathogenic factors of
idiopathic or secondary glomerulopathies. This study confirms the
existence of CI in various nephropathies. We used two methods: 1) The
PEG presipitation (3.5%) method and 2) The immunodiffusion PEG-C4
method. We tested 570 samples of blood serum from ten groups of
patients: I) The control group (60 normal adults); 2) acute post infection
GN (10 patients); 3) minimal changes GN (19 patients); 4) membranous
nephropathy (12 patients); 5) membranoproliferative GN (12 patients);
6) lgA-nephropathy (15 patients); 7) focal segmental glomerulosclerosis
(17 patients); 18) lupus nephritis (21 patients); 9) Wegener's granulo-
matosis (7 patients); 10) End—stage chronic renal failure (82 patients).
High levels Cl were found in: I) SLE nephritis (85%); 2) acute
postinfection GN (90%); 3) Wegener's granulomatosis (50%); 4) tgA-
nephropathy (20%); 5) FSGS (18%); 6) membranous nephropathy
(30%); 7) minimal changes GN (12%); 8) membranoproliferative GN(14%). In conclusion, it seems that the estimation of CI is very
important for the course and prognosis of immune complex nephritides.
Immunotherapy in experimental immune complex glomerulonephritis(ICGN) in rabbits. P.M. Zeis, L. Nakopoulou, D. Gourgiotis, I.
Pierroutsakos, 2nd Dept. of Paediatrics and Department of Pathology,
University of Athens, Athens, Greece. ICGN was induced in rabbits by
intraperitoneal injection of human albumin (HA) for 5 days. An ap-
proach was attempted in treating the GN by excess antigen, by which
either the deposition of IC in the mesangium might be prevented or that
binding of injected antigen excess to IC present in the mesangium might
accelerate the process of resolution. The results were compared with
those obtained from rabbits which received low dose of HA +
prednisolone. Seventy—five rabbits were divided in 4 groups. Controls
(I), Determination of proper dose of HA (2), high (3) and low dose of
HA + prednisolone (4). Normal values of blood urea, creatinine, urine
lactic dehydrogenase, alkaline phosphatase activities were obtained.
Group 2 was divided in 3 subgroups: in each HA was given in low (300
mg/kg), medium (700 mg/kg) and high (I g/kg) dose. The animals were
sacrificed and the kidneys removed for microscopy on day IS. lm-
munofluorescence (IF) was positive with lgG and C3 deposition in the
capillary basement membrane of the glomeruli in low, slightly positive
in medium and negative in high dose. Groups 3 and 4 were studied for
a total of 4 months. Blood, urine and renal histology were compared in
given periods. The results of those groups indicated intact renal
function in 3 and mild fall in 4. The urinary activity of the enzymes was
increased in 4. Light microscopy showed transient mesangial hyperpla-
sia in 3 and progressed in 4. The IF was negative in 3 and positive in 4.
In conclusion the high dose of HA had a favourable result. Perhaps, in
future the ICGN could be treated with disturbance of the ratio
antigen/antibody by increasing the antigen than reducing the organism's
ability in producing antibodies.
Poor response of idiopathic membranous glomerulonephritis (I.M.GN.)
to alternated courses of steroids and chlorambucil. Gr. Vosnides, K.
Edipidis, F. Sotsiou, G. Papadakis, M. Siakotos, H. Lemoniatou, P.
Kaloheretis, A. Billis, Division of Nephrology, Evangelismos Hospital,
Athens, Greece. In order to evaluate the therapeutic effect of steroids
and chlorambucil in L.M.GN., these drugs were given in alternated
monthly courses for six months to 14 nephrotic patients, aged 16 to 60
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years, with histologically proven IMGN and normal renal function
(Group I). For comparison 11 patients who received no treatment were
used (Group II). There were no significant differences in age, severity of
proteinuria, serum creatinine levels and histological stage of GN
between the two groups. The follow—up period from renal biopsy was
36.6 17.2 and 30.9 11.1 months for Groups I and II, respectively,
and from the end of treatment (for Group 1)19.2 9.1 months. At the
end of the follow—up period, complete or partial remission of the
nephrotic syndrome, which lasted 18 to 36 months, was observed in 2
patients of each Group and deterioration of renal function in 2 pts of Group
I and 3 of Group II. These results indicate that, in contrast to previous
reports, this regimen has no significant therapeutic effect in IMGN.
Histological findings from the kidney and the sural nerve in essential
mixed cryoglobulinemia. P. Ziroyanis, M. Mavrikakis, T. Psimmaras,
Siotsou Flora, Davaki Ekaterini, Evangelopoulou Ekaterini, K.
Papageorgioy, Department of Clinical Therapeutics, Unit, of Athens.
Greece. The essential mixed cryoglobulinaemia is characterized by the
occurence of immunoglobulins precipitating in the cold. The clinical
manifestations resulting from vasculitis affect skin, kidneys, liver, lungs
and rarely the gut and nervous system. A 56—year—old patient with
arthralgia, Raynand's phenomenon, symmetrical purpuric rash of the
lower legs for 4 years and numbness and burnings of the lower legs for
the last year was studied. Recently she developed drowsiness and
oedema with uremia. Immunoelectrophoresis showed mixed cryoglob-
ulinaemia IgM-IgG, in which 1gM was a k-chain monaclonal type. A
difference in peripheral WCC between automatic counter and the
manual (Neubauer slide) method was observed. Biopsy of the right
sural nerve showed demyelinating disease and secondary axonal degen-
eration and marked pevivascular infiltration with white cells while
immunocytochemical examination showed 1gM and complement depos-
its in the destroyed myelin and the walls of the trophic vessels; findings
which were confirmed by electron microscopy. Renal biopsy showed
mesangiocapillary type changes with nodular changes of the glomeruli.
Immunofluorescence showed subepithelial deposits of IgG, IgA, Cq C3.
It's concluded that the deposits of immunocomplexes may be different
in different organs and we emphasize the necessity for measuring the
white cells in these patients by traditional methods.
Lung perfusion scan for diagnosis of pulmonary embolism in patients
with nephrotic syndrome. K. Edipidis, K. Alevizaki, Gr. Vosnides, G.
Papadakis, M. Siakotos, N. Nikolopoulou, J. Kakavas, D. Vasilakakis,
L. Sdrakas, A. Billis, Department of Renal Medicine and Nuclear
Medicine, Evangelismos" Hospital, Athens, Greece. Over a six year
period, 85 lung perfusion scans were done in 54 patients (pts), aged 16
to 60 years, with nephrotic syndrome due to idiopathic membranous
glomerulonephritis (GN) (33 pts), niesangioproliferative GN (II pts),
minimal change disease (4 pts) and systemic lupus erythematosus (6
pts). In 43 of these pts venograms of the renal veins (40 pts) or the veins
of the lower limbs up to the inferior vena cava (3 pts), were also
performed. The lung scans were done with the use of y-camera
following iv. administration of 99 mTc-MAA and the venograms by
retrograde catheterization of the femoral vein. The evaluation of scans
was done by the Nuclear Medicine Department without prior clinical
information. Thirteen of the 14 pts (92,8%) with an abnormal lung scan,
that is suggestive of pulmonary embolism, had clinical and/or veno-
graphic evidence of thromboembolic episodes. In contrast, of the 40
patients with a normal (23 pts) or "doubtful" (17 pts) scan only two (one
from each group) had clinical and/or venographic evidence of venous
thrombosis. These observations suggest that lung perfusion scan is a
simple, non-invasive and reliable technique for the diagnosis of pulmo-
nary embolism in pts with the nephrotic syndrome.
Urinary glycosaminoglycans in calcium nephrolithiasis. D. Mayopou-
lou-Sy,nvoulidis, TH. Mouniokalakis, A. Katirtzoglou, G. Digenis, H.
Diavidovitch—Consta, A. Symvoulidis, Second Department of Internal
Medicine, Athens University, Hippocration Hospital. Glycosaminogly-
cans (GAGs) are considered to contribute significantly to the inhibition
of calcium oxalate crystallization in urine. Therefore, a decreased
excretion would be expected in stone formers. However, the results of
the few existing studies are contradictory. In 88 calcium stone formers
(60 men, 28 women, mean age 39.4 13.3 years) and 26 normal controls
(13 men, 13 women, mean age 37.5 9.3 years) the 24-hour excretion
of GAGs was studied with the method of Whiteman (measurement of
Alcian blue—glycosaminoglycan complexes). The excretion of creati-
nine, uric acid, calcium, phosphorus, magnesium, oxalate and citrate
was also determined. There was no statistically significant difference in
the daily excretion of GAGs between the two groups (42.4 23.3
mg/day in stone formers vs. 36.9 21.4 mg/day in controls), while the
excretion of calcium (207.1 97.6 mg/day vs. 157.2 65.6 mg/day, P
<0.01), oxalate (31.17 16.9 mg/day vs. 21.9 8.8 mg/day P < 0.001)
and uric acid (635.8 274.3 mg/day vs. 530.5 215.2 mg/day, P < 0.05)
was greater in the stone formers. The comparison between the two
groups of the quotient of the main promoters (calcium x oxalate x uric
acid) to the main inhibitors (GAGs )< citrate) of calcium oxalate crystalli-
zation, each expressed as its concentration ratio to creatinine, showed that
this was significantly higher in the stone farmers (P < 0.01). It is concluded
that stone farmers have defective GAGs' excretion in relation to increased
excretion of promoters of calcium oxalate crystallization.
The pharmacological activity of vitamin D3 in the hypercalciuria. I.
Voscaki, S. Sbyrakis, C. Mengrelli, K. Vrettos, Institute of Child
Health, Athens and Paediatric Clinic of child Hospital 'Aghia
Sophia", Greece. For the purpose of studying the effect of serum
25-hydroxyvitamin D (2SOHD) levels on absorptive and renal
hypercalciuria (HCU) in children with nephrolithiasis in Groups A) 10
normal children, and B) 18 children with renal HCU and 7 children with
absorptive HCU, serum 250HD, calcium (Ca), phosphorus (P) and
creatinine (Cr) were measured. Ca, P, Cr and hydroxyproline (HO-Pr)
were also measured in a) fasting 3-hours urine collection and b)
in 24-hours urine collection. Renal tubular reabsorption of Ca(TmCaJ
GFR) and P (TmP/GFR), endogenous excretion of Ca(UCaJUCr) and
Ho-Pr (UOHPr/UCr) were calculated. Statistically significant differ-
ences between groups A and B were in 250HD (P < 0.025, P (P <
0.025), UCa/UCr (P < 0.01), UHO-Pr/Ur (P < 0.025) TmCaIGFR (P
<0.01) and TmP/GFR (P < 0.01). In group B in 7 patients who had low
serum levels of 250HD, TmCa/GFR was statistically significant higher
(P < 0.005). A negative correlation was found between 250HD and
TmCaJGFR in patients with low levels of 250HD while no correlation
was found in the patients of all group. In three patients with renal UCU
and low levels of 250HD administered vitamin D per os. In conclusion:
1) the renal HCU causes secondary hyperparathyreodism (H.P.T); 2)
this secondary H.P.T. some cases is due to the low levels of 250HD; 3)
the absorptive HCU was not associated with the levels of 250HD in
serum; 4) the hypercalciuria is restored by means of raising the levels of
250HD in the serum.
Urinary y-glutamyl transferase for detection of drug—induced
nephrotoxicity. C. Tegos, A. Tsoukas, J. Adamopoulos, S. Vafiadis, A.
Kravaritis, P. Panourgias, M. Adreopoulou, C. Kouttos, Clinical
Research Laboratory and Department of Nephrology 401 General
Hospital of Army and Veterans Hospital, Greece. Urinary y-glutamyl
transferase (y-GT, EC 2.3.2.2) activity was measured in 40 subjects
with normal renal function before and after antibiotic therapy. Subjects
were divided in 5 groups and 4-days of antibiotic therapy was given as
follows: 1st group ampicillin (4 g/day); 2nd group cefamandole (4 g/day);
3rd group gentamicin (0.240 g/day); 4th group tobramycin (0.240 g/day)
and 5th group amicacin (Ig/day). Results are given below:
Group
'y-GT activity
(U/24hr urine, Mean SD)
PBefore After
1st
2nd
3rd
4th
5th
74.12 17.90 72.00 17.73
87.70 18.30 108.60 29.65
65.00 12.86 194.00 82.71
76.62 16.90 116.50 34.19
81.00 18.89 229.25 45.40
>0.1
<0.05
<0.01
<0.01
<0.001
a paired t-test
Urinary y-GT activity was significantly increased in subjects treated
with aminoglycosides. Moreover, 3 patients overtreated with amino-
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glycosides were found having 10 fold y-GT activity in urine. Therefore,
it seems that y-GT may represent a useful marker for mephrotoxicity,
the sensitivity of which is increased by measuring the enzymouria in
24-hours urine and more specifically by measuring the enzymatic
activity of urine membranes.
Acute changes of the renal function after i.v. nifedipine (NF) adminis-
tration in hydropenic dogs. T. Natscheh, E. Alexopoulos, A.
Dimitriadis, S. Kalpakoglou, M. Papadimitriou, Second Prop. Depart-
ment of Medicine, Aristotelian University of Thessaloniki, Hippokrazio
Hospital, Greece. It has been already shown that the preventive
administration of NF, a calcium entry blocker agent has a favorable
effect on the course of experimental ARF. In this study we evaluated
the acute effect of the iv. administration of NF on the renal function in
dogs. Two groups of 10 animals each were used. After bilateral flank
incisions, both kidneys were exposed and renal function was deter-
mined. Then the renal pedicle on one side was clamped and 10 sg/kg
body wt of NF (Group I) or placebo (Group H) were infused i.v. In the
subsequent 10 minutes the renal function of the other kidney was
determined. There was a significant fall of the mean systolic arterial
blood pressure (SBP) in group I (from 145 to 122 mm Hg) with a
concomitant reduction of the mean urine flow rate (from 0.73 to 0.49
mI/mm). Clearances of creatinine and urea decreased significantly (from
19.64 to 12.27 mI/mm and from 15.34 to 10.02 mI/mm, respectively),
while fractional excretion of osmoles (FEosm) increased significantly
(from 5.41 to 7.14%). Free water clearance (CH2O) decreased from
—0.46 to —0.52 mI/mm. In contrary fractional excretion of sodium
(FENa) increased from 3.58 to 3.78% although the differences were not
statistically significant. No significant differences were observed in
Group II. In conclusion, acute administration of NF produced rapidly a
significant fall of SI3P with cocomitant reduction of the urine output and
the glomerular filtration rate in hydropenic dogs. Despite this phenom-
enon NF acting by increasing FENa and FEOsm seems to have a mild
diuretic effect.
Fluctuations of serum iron in acute renal failure. N. Zoumbaridis, G.
Vayonas, M. Arvanitidoy—Vayonas, S. Faitsis, Department of Internal
Medicine, Renal Unit, Second Hospital of IKA, Thessaloniki, Greece.
The chance observation of low serum iron values in acute renal failure
(ARF) and the complete lack of similar references in the literature
prompted this investigation. Serum iron and TIBC was measured in
nine patients with ARF due to various causes. The blood sample were
drown in the first 48 hours after the onset of ARF and again after 8 to
35 days, that is, after complete recovery. In five patients the serum
ferritin level was also determined at the same time. Serum iron ranged
from 20 to 32 sg% (mean value 24.6 sg%) in the first sample. In the
second sample from six patients who recovered, the iron value rose
ranging from 46 to 78 g% (mean value 59 g%). (P < 0.001). TIBC and
ferritin levels were at the upper normal limit. Haematocrit values
remained unchanged in both measurements. We conclude that with the
onset of ARF, regardless of its cause, a dramatic reduction of serm iron
level is observed, whereas the recovery of renal function is followed by
a reversal towards normal levels. An iron redistribution, for unknown
reasons, seems to explain better this phenomenon.
Determination of "the osmostat" parameters in patients with the
nephrotic syndrome. N. Papagalanis, K. Christodulidou, J. Kimburis,
J. Boutopoulos, L. Doumas, G. Kalycakis, E. Koulouridis, G.
Kostoyianni, G. Straligea and V. Chatziconstantinou, Department of
Clinical Nephrology General Hospital of Athens, and Department of
Clinical Nephrology 7th Hospital of IKA, Athens, Greece. To verify
whether or not the A-VP secretion corresponds appropriately to the
changes of Pom, 9 nephrotic patients and 5 normal control subjects
were studied in basal conditions and following a water load (20 mI/kg in
30 mm). In the basal condition the nephrotic patients had a lower PV
(38.6 1.88 mI/kg) than the control subjects (48.2 0.84 mI/kg) P <
0.05, and lower POEm (279 2.41 mOsm/kg versus 289.6 1.72
mOsm/kg, P < 0.05), in the presence of a higher plasma A-VP
concentration (6.8 0.5 pg/mI versus 3.6 0.21 Jml, P < 0.05) and a
higher Uosm (826 56.5 mOsm/kg and 796.2 34.59 mOsm/kg for
patients and control subjects, respectively). Following the water load
control subjects reached a minimum Uo,,, of8l .9 2.21 mOsm/kg at 60
minutes (P < 0.01). The plasma A-VP concentration decreased signif-
icantly (1.9 0.11 pg/mI, P < 0.001) as did the P0.,, (281.4 2.79
mOsm/kg P < 0.05). The picture was different in nephrotic patients:
although Uosm was reduced at 60 minutes, its value (159.8 7 .02
mOsm kg remained significantly higher than the corresponding value of
of control subjects (P < 0.001). At the same time plasma AVP had
a N.S. reduction (4.94 0.37 pg/mI) although Pom was at a very low
level (268.6 1.76 mOsm/kg, P < 0.01). A significant direct correlation
was observed between plasma AVP and POm in control subjects both in
basal condition (r = 0.80, AVPO,07 Posm — 16,86, P < 0.05) and after
the water load (r 0.93, A-VP-0.039 P05,,, — 0.11, P < 0.01) but not in
nephrotic patients. Plasma A-VP was inversely correlated with PV in
nephrotic patients (r = —0.66, PRA = —0.15 PV + 89, P < 0.05). Our
results demonstrate a volume—mediated secretion of ADH in neprhotic
syndrome, which is responsible for inappropriately—high urine osmolal-
ity, under water diuresis conditions.
CyA hepatotoxicity in renal transplant recipients. Th. Viassis, I.
Papatheofanis, K. Megaloconomo, S. Kyriakides, S. Garbis, I.
Karavasilis, E. Vafiadou, I. Homatas. Renal Transplant Unit, Laiko
General Hospital, Athens, Greece. Twenty—nine renal transplant recip-
ients on CyA and steroid immunosuppression treatment were studied.
An initial CyA dose of 10 mg/kg/24 hr and medrol of 20 mg/24 hr was
administered for the first month. Further CyA doses were determined
by blood levels and complications of the drug. Liver function tests were
performed routinely. Impairment of liver function was shown by 13 of
the 29 patients. A rise in serum bilirubin occured in 8 patients, elevation
in alk.phophatase in 10, -GT in 8 and transaminases in 5. (Elevations
were considered only after they had been confirmed on 3 consecutive
values). Reduction of CyA dose resulted in recovery of liver function in
7 out of 13 patients. In other 4 patients CyA was converted to
Azatioprine. This was necessary in two of them, one for nephrotoxicity
coexistance and the other for serious hepatotoxic induced effect of
simultaneous prophylactic administration of anti-TBC regime. (isonia-
zide + rifampicin). In the last two patients CyA discontinuation
restored to normal the liver function tests in one of them while did not
had any effect on the other. It is obvious that CyA-induced hepatotox-
icity is frequent in renal transplant recipients and this is dose depen-
dent. Combined administration with isoniazide rifampicin may seri-
ously harm the liver.
Effect of oral calcitriol on the hyperparathyroidism of patients on
maintenance hemodialysis. M. Pazianas, J.B. Eastwood, M.E. Phillips,
Departments of Medicine, Charing Cross & St George's Hospitals,
London, England. One hundred and six patients on maintenance
haemodialysis at Channg Cross Hospital for at least one year were
given oral calcitriol (l.25-(OH)2 Vit D3) 0.25 to 0.50 sJday for I to 7
years. The dose was lowered if the pre-dialysis plasma calcium reached
3.00 mmol/liter. Radiographs of the hands were taken at least once a
year, and were assessed in the following manner: all the films from a
particular patient (up to 20 films) were looked at, without knowledge of
the chronological sequence or identity of the patients. Each film was
scored on a scale from 0 to 4 according to the severity of hyperpara-
thyroidism (0 = normal, 4 = severe erosions including long bones).
After assessment, the results were recorded and displayed in chrono-
logical secquence. Sixty—six patients had normal radiograpsh at the
time of starting calcitriol; 60 remained normal but in 6 erosions
developed. In the other 40 patients initial radiographs were abnormal; in
17 there was radiological improvement and in only 9 did the bone
disease progress. In 14 there was no appreciable change. These findings
add further weight to the view that administration of oral calcitriol is
capable of preventing or delaying the development of radiological
sub-periostial erosions in hemodialysis patients. We are at present
undertaking an analysis of the films of a matched gorup of patients who
were not given calcitriol. Comparison of the groups will, it is hoped,
show whether calcitirol is effective treatment for hyperparathyroidims
in dialysis patients.
59Fe and 51Cr studies in patients on chronic hemodialysis. P.N.
Ziroyanis, M. Kesse—Elia, V. AlevizouTerzaki, S. Gerali, H. Gyflaki,
Department of Clinical Therapeutics, University of Athens, Alexandra
Hospital, Greece. Chronic renal failure (CRF) is usually accompanied-
866 Abstracts
by anemia. For this a reduce plasma erythropoietin and shorterning of
the red cell lifespan have been implicated, Nine patients with CRF, who
were under hemodialysis (HD) from 30 to 96 months, were studied.
Seven of them were anemic for the first 18 months of HD (Hct 18 to
25%) but later improved the blood picture (Hct 36 to 50%). None of
these patients suffered from hepatitis and all were HBsAG-ve. The
other two, throughout the period of HD were anemic (Hct 15% and
22%, respectively). In these patients erythropoiesis has been studied
with 59Fe and red cell survival time with 5'Cr performed. The results of
the seven patients were: plasma 59Fe half clearance time 31 to 140 mm
(m.v. 72.5 NV 60 to 120 mm). Red cell 59Fe uptake 42 to 98% (m.v.
74.1% NV 85 to 100%). Plasma iron turnover rate 0.13 to 0.90
mg/kg/day (m.v. 0.30, NV 0.46 to 0.75). Red cell iron turnover rate 0.12
to 0.60 mg/kg/day (m.v. 0.30 NV 0.43 to 0.72). 5tCr half survival time 25
to 64 days (m.v. 38 NV 26 to 36 days). The results showed that
erythropoiesis is effective though sometimes lower than normal and the
51Cr half survival time normal. The two anemic patients had decreased
red cell 59Fe uptake and short 5tCr half clearance time. In conclusion,
patients with improvement of blood picture during hemodialysis show
improvement in erythropoiesis and red cell survival time.
Lack of correlation between histological changes of the peritoneal
membrane and ultrafiltration in CAPD. K. Tsomi, A. Katirtzoglou, N.
Apostolidis, K. Platsakis, T. Mountokalakis, Department of Pathology,
Children's Hospital, Pan. and Aglaia Kyriakou, 2nd Department of
Internal Medicine Athens University Medical School, Hippokration
Hospital, Athens, Greece. Histological changes of the peritoneal mem-
brane such as loss of mesothelial cells and superficial fibrosis have been
proposed as a cause of the loss of ultrafiltration in CAPD patients. To
evaluate the relationship between histological changes and ultrafiltra-
tion capacity of the peritoneal membrane, the morphology of the
peritoneum was examined in 4 patients who had experienced repeated
episodes of microbial peritonitis during CAPD. Biopsies were per-
formed at the time of removal of peritoneal catheter. In one patient two
additional biopsies were done at the time of catheter replacement, and
when catheter was again removed after 1.5 and 9 months, respectively,
while a second biopsy was performed following 7 months, when
catheter was again removed, in other patient. In all biopsy specimens
the following main histological changes were found: a) loss of
mesothelial cells of the peritoneal surface in association with exudative
elements (fibrin and inflammatory cells), b) superficial fibrosis and c)
forcing body granulomas. In all patients, no appreciable changes were
documented when ultrafiltration capacity of the peritoneal membrane,
evaluated by an appropriate method, was compared at the beginning of
CAPD and 2 to 3 days before biopsy. It is concluded that the above
istological lesions are not necessarily etiologically related to functional
changes of the peritoneal membrane.
Influence of dialysate osmolacity and exchange time on kinetics of water
and electrolytes in CAPD. A. Dimitriadis, S. Antoniou, G. Lakassa, P.
Lagoudaki—Keklikian, First Department of Internal Medicine, Agios
Dimitrios Hospital, Thessaloniki, Greece. Ultrafiltration of peritoneum
and kinetics of electrolytes are of special interest in patients starting
CAPD, overhydrated, etc. Contradictory opinions exist on the effec-
tiveness of different dialysate osmolalities and the exchange time. Ten
patients on CAPD for 3 to 23 months underwent exchanges with 21. of
lactated solution with glucose 1.5% (A) or 4% (B) for l(A,-B,) or
4(A4,B4) hours. Net ultrafiltration and changes of K, Na, Ca, Mg and P
in the blood and the dialysate were studied. Net ultrafiltration was
greater for B, and B4, without of exchange time (A1 A4, B, B4).
Loss of H20 (mi/i mm) declined over time (A,:0.3, A4:0.l6, B,:4.7,
B4:2. I). Total loss of K (mEq/bag) was greater with B and influenced by
time (A,:5.l 0.9, B,:6.2 1.4, A4:5.7 2.9, B4:8.6 3.8). Loss of
Mg was 0.81 mEq/bag for B4, 0.26 for B, and negligable for A, and A4.
Absorption of Ca in A, (28 mg), A4 (26 mg), B, (4.5 mg) and secretion
of 10 mg in B4 were observed. Loss of P is greater with B and over time
(B4> B, > A4 > A,). Of special significance were the changes of Na.
In A, and A4 reabsorption of Na (37 and 47 mEq/bag) was observed
while in B, and B4 existed excretion of Na (3 and 31 mEq/bag). It can
be concluded that solutions of 4% have a high ultrafiltration but led to
loss of K, Mg, and Na greater for 4 hour exchanges. Solutions of 1.5%
can correct hyponatremia and hypocalcemia, with less effect to
overhydration.
Influence of Dialysate osmolality and exchange time on peritoneal
clearance, blood osmolality and acid—base equilibrium in CAPD. A.
dimitriadis, G. Lakassas, S. Antoniou, N. Kakayas, 1st Dept. mt. Med.
AGIOS DIMITRIOS Hosp., Thessaloniki, Greece. Patients starting
CAPD or who are overhydrated need often exchanges with solution of
different osmolality and/or short duration, with contradictory opinion
about concomittant alterations of peritoneal clearance, osmotic effects
and acid—base equilibrium. Ten patients, on CAPD for 3 to 23 months,
underwent exchanges for 1 or 4 hours with 2 1 lactated solutions with
I .5g% (A, ,A4) or 4 g% (B, ,B4) glucose, Clearances of urea, creatinine
and uric acid, changes of glucose and osmolality of plasma and dialysate
and alterations of blood pH, pCO2, p02, HCO3, TCO2 were studied.
Maximum of clearances was achieved at 1 hour (B, A,) and declined at
4 hours from 39 to 50% (P <0.01). While blood glucose rised in all cases
(+A%: A,l6.5, B,lO.9, A459.2, B418.9) plasma osmolality was un-
changed, except A4(+4%). In contrast changes in dialysate were
pronounced with decrease of osmolality (—%: A,13.5, B,l7, A415.5,
B436.5) and of glucose. Protein loss (gfbag) reached maximum at I hour
and remained stable (A,2.9 1.0, A43.9 1.7, B,3.9 2.2, B43.7
3.0). All patients were acidotic as well before as after all kind of
exchanges. PO2 and pCO2 did not change. In conclusion maximum of
clearances is observed at I hour with significant decline at 4 hours.
Despite profound changes of dialysate osmolality, CAPD does not
provoke perceptible acute changes of blood osmolality and acid—base
equilibrium.
Effect of a high essential amino acids/high calorie diet on growth of
infants with chronic renal failure (CRF). C.J. Stefanidis, J. Boukouvala
and M. I/ia, Second Department of Pediatrics, University of Athens,
Athens, Greece. To assess the effects of specific dietary management
(SDM) on 5 children with CRF (2—il months old) various parameters
were compared before and after a 5 to 19 month period. Protein and
calorie intake were between 1.5 and 2glkg/day and 110 to 130
cal/kg/day, respectively. Fifty—two to 55% of protein intake consisted of
essential amino acids. All patients had oral Al(OH)3 CaCO3, NaHCO3,
FeSO4, and vitamins B complex, C, l- (OH)D3, and folic acid. Patients
were evaluated at monthly intervals. Height and weight velocity were
—0.4 and —0.5 sD/month, respectively, and increased to +0.01 and
+0.06 sD/month (P < 0.001). Arm muscle circumference and triceps
skin—fold thickness also increased significantly (P = 0.02 and 0.002).
Serum albumin and pseudocholinesterase exhibited similar improve-
ment (P = 0.02 and 0.01). Glomerular filtration rate decreased from 14.4
5 to 12.8 6 ml/min/l.73m (P >0.05) during the SDM period. These
results suggest the dietary management contributed to the improved
growth velocity in the patients. There were substantial increases in both
muscle mass and total body fat, with the latter being most marked. At
the end of the study, there was no significant deterioration in renal
function of the study group.
Relationship between renal zinc excretion (UzV) and Urine flow (V) In
healthy volunteers. G. Theodoulou, S. Dourakis, D. Mayopoulou—Sym-
vou/idou, T. Mountokalakis, Second Medical Department, University
of Athens, Athens, Greece. To test the hypothesis that diuretic—induced
increase in U5V is a consequence of the increased V, a series of
experiments was performed in two groups of healthy volunteers. In the
first group (II men, aged 35 to 45 years) furosemide (F) was given i.v.
(20 mg) alone or in combination with saline loading. F resulted in a
sigificant (paired 1-test) increase in mean (±sEM) V from 0.67 0.05 to
3.53 0.10 mI/mm and in UzV from 11.00 1.16 to 27.25 2.74
nmollmin, and in a significant decrease in urinary zinc concentration
(Uzn) (from 17.65 2.13 to 7.81 0.86 smol/liter. F combined with
saline load resulted in a greater increase of V (5.33 0.90 mI/mm) and
of U,,V (71.10 45.50 nmol/min) and in no significant change in Uzn
(12.57 2.03 smol/liter. In the second group of volunteers (2 men and
4 women, aged 25 to 40 years) V was modified by an oral water load (15
mi/kg), by mannitol infusion or by 12 hour fluid deprivation. The
increase in V produced by water diuresis (from 0.46 0.08 to 1.95
0.31 mI/mm) or by osmotic diuresis (2.15 0.20 mI/mm) was ac-
comparied by a significant increase of Uz,,V (from 5.68 0.88 to 6.88
0.95 and 8.20 1.72 nmol/min, respectively) and by a significant
decrease of U,, (from 12.68 1.63 to 4.39 1.32 and 2.87 0.96
mol/liter, respectively), while fluid deprivation resulted in decreased
U,,V (3.64 0.53 nmol/min) and in no significant change in Uzn (9.05
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1.69 mol/liter). It is concluded that the effect of diuretics on U,,V
is largely secondary to the increased V produced by these agents.
The evaluation of the renal artery by Digital Substraction Angiography.
P.K. Spanos, N. Vouyiouglis, M. Toumpouras, G. Louridas, D.P.
Lazarides. Cardiovascular clinic of the AHEPA Hospital, Thessaloniki,
Greece, Digital subtraction angiography is a new method for evaluation
of the arterial and venous system. At the Cardiosurgical unit and the
Hemodynamic Laboratory of the AHEPA Hospital during the period
form 1/2/85 to 30/12/85, 650 examinations were performed with DSA. In
20 patients DSA was done in order to evaluate the renal artery. The
underlying pathology was abdominal aortic aneurysm in 6 patients, 5
were potential renal donors, 4 renal recipients and 4 were studied with
the probable diagnosis of renovascular hypertension. Finally one other
patient was studied in order to check postoperatively the result of her
renal angioplasty. Thirty examinations were performed in these pa-
tients. In 26 venous infusion was done and in the rest 4 arterial.
Satisfactory results with the method were obtained in 19/20 of the
patients. Five of the 20 were out patients and the rest were hospitalized.
There were no complications and there was no worsening of renal
function in the patients examined with DSA. Digital substruction
angiography has become the procedure of choice in our clinic in order
to study patients with these problems.
Plasma exchange (PE) in the treatment of rapidly progressive glomer-
ulonephritis (RPGN). G. Sakellariou, E. Paschalidou, Th. Tsobanelis,
M. Papadimitriou, Second Prop. Dept of Medicine, University of
Thessaloniki, Thessaloniki, Greece. Plasma exchange is increasingly
used in treatment of a growing number of unsolved problems in patients
with immune—complex regular diseases. From 1983 till 1985 9 patients
(mean age 26 years, range 8 to 46 years) with RPGN, idiopathic or
secondary were treated by PE-methyiprednisolone pulses and/or
cyclophosphamide. Five patients presented an extracerbation of sys-
temic disease (2 Wegener's granulomatosis, 3 SLE), 2 patients had
idiopathic RPGN, I post-infectious GN and I membranous ON. Renal
biopsy showed crescentic glomerulonephritis in all cases. PE treatment
was carried out by using a polypropene membrane filter (Curesis). In
each session 3 to 4 liters of plasma were filtered and simultaneously
replaced with 3.5 to 4.0% albumin—Ringer's lactate solution. Three out
of 9 patients were oligoanuric at the first admission to the Unit. The
mean value of circulating immunocomplexes (methods PEG 3.5%) was
0.120 before starting treatment and decreased to 0.078 immediately
after. The mean values of serum creatinine and blood urea were 6.2
mg% and 1.67 g% before and 2.3 mg% and 0.90 g% after the treatment
was completed, respectively. PE had a favorable effect on the renal
function in 6/9 patients while no such effect was observed in the
oligoanuric patients. In conclusion, PE therapy seems to be useful in
the management of severe systemic disease affecting the kidney and in
some cases of idiopathic RPGN without oligoanuria.
Urinary oxalate excretion in patients with idiopathic hypercalciuria.
Effect of thiazides and cellulose phosphate on (a) urinary oxalate and (b)
stone formation frequency (5 year follow—up). G. Kostoyianni—
Papagalani, N. Papagalanis, J. Saklaridis, P. Sakelariou, A. Thanos,
J. Boutopoulos, A. Lagouranis, E. Koulouridis, N. Nicolakakis, G.
Kalycakis, V. Hatziconstantinou, N. Davillas, Urology Department,
Athens General Hospital and the Renal Unit, 7th Hospital of IKA,
Athens, Greece. A quantitative estimation of urinary oxalate excreption
was performed by the method of Hodginson and Williams in 34 patients
with idiopathic hypercalciuria (IHCa) type 1, 27 patients with IHCa type
II and 11 patients with renal hypercalciuria (RHCa). Twenty—four hour
oxalate excretion 1.73 m2 body surface area was found to be (a) 41.4
1.95 mg in lHCa type I patients, (b) 32.9 1.5 mg in IHCa type 11
patients, and 42.6 4.21 mg in RHCa type. Thus, oxalate exereption
was higher in lHCa, I patients than IHCa, II patients (P < 0.01) and
IHCa, LI patients, were excreting less oxalate when compared to RHCa
patients (P < 0.001). Eight LHCa I patients and two IHCa, II patients
received long—term treatment by thiazides initially and sodium cellulose
phosphate (SCF) later along with a low salt, low calcium diet, and
followed—up for 6 years. Thizides+diet treatment resulted in a signifi-
cant decrease of calcium excretion (from 290 9,56 to 168.7 12.1
mg/24 hr). Addition of SCF resulted in a further decrease of calcium
excretion to 118 5.27 mg/24 hr. Oxalate excreption was not influenced
significantly by thiazides, whereas it was substantially increased by the
addition of SCF after the first year of treatment (61.16 2.55 mg124 hr).
This combined treatment decreased the stone formation frequency from
0.55 stones patient/year (before treatment) to 0.2 stones/patient/year.
Evaluation of the hypothalmic hypophyseal adrenal axis in patients
with chronic renal failure by the corticotropin—releasing factor stimula-
tion test. K.C. Siamopoulos, E. Eleftherieadis, M. V. Pappas, V.
Kosmas, 0. Tsolas, Department of Nephrology and the University
Biochemical Laboratory, General Hospital 'G. Hatzikosta", loan-
nina, Greece. Studies of the hypothalamic hypophyseal adrenal axis
(HHAA) after suppression or stimulation by various tests in patients
with chronic renal failure have shown dysfunction of the axis.
Corticotropin—releasing factor (CRF), which is produced by the hypo-
thalamus, is one of the factors that modulates the secretion of the
adenocorticotropic hormone (ACTH) by the pituitary gland. In this
study we evaluated the HHAA in patients with chronic renal failure by
the intravenous administration of ovine synthetic CRF (I pg/kg body
wt). Eight patients had a moderate to severe chronic renal failure (c.r.f.)
and 20 were receiving long—term hemodialysis. Six normal subjects
were studied as controls. The evaluation of the HHAA was performed
by measuring serum cortisol before and after the administration of CRF
in sequential serum samples for 180 minutes. The results showed
statistically significant increases in basal serum cortisol in both groups
of patients and particularly in the c.r.f. group, compared with the
controls. Nevertheless, the cortisol responses to CRF were similar in
both patients and normals. In conclusion, the HHAA in chronic renal
failure patients preserves its functional integrity.
Low triiodothyronine syndrome in patients with chronic renal failure.
P. Kontessis, Th. Tillis, N. Kallivretakis, G. Mortzos, S. Voudikiari,
Ch. Velentzas, 2nd Department of Internal Medicine, University of
Athens, Hippokration Hospital, Athens, Greece. Thirty—one patients
with chronic renal failure from which 9 were treated conservatively
(group A), 17 with hemodialysis (group B) and 5 with CAPD (group C)
were investigated for low triiodothyronine syndrome (LT3S) by deter-
mination of the following parameters of thyroid gland function: I) total
triiodothyronine serum (T3); 2) total reverse triiodothyronine serum
(Ri'3); 3) total thyroxine serum, and 4) TSH serum. On the patients of
group B was determined the level of both triiodothyronines before and
after hemodialysis. In addition prolactine serum level was determined
in all patients. On the base of T3 serum level the LT3S was detected in
the patients of group A (T3:0.45 0.2 ng/ml, n.y.: 0.7 to 2 ng/ml) and in
group C (T3: 0.6 0.14 ng/ml). But on the base of RT3 serum level, the
LT3S was detected in all patients. (Group A:RT3 = 0.59 0.14 ng/ml,
group B:RT3 = 0.43 0.4 ng/ml, group C:0.43 0.17 ng/ml) (n.y.: 0.09
to 0.35 ng/ml). Both total thyroxine and TSH levels of serum were
found in normal limits. The finding was very important in group B that
the LT3S disappeared just after the end of hemodialysis. Prolactin
serum level in all patients was increased.
Estimation of parathyroid function in patients with advanced crhronic
renal failure (CRF): Determinations of nephrogenous cAMP (NcAMP). S.
Koutmos, M. Siakotos, A. Pappas, Ch. Nikolou, P. Mavrokephalos, N.
Nicolopoulou, A. Argyropoulos, A. Billis, P. Singhellakis, Departments
of Nephrology and of Endocrinology "Evanghelismos" Hospital Ath-
ens, Department of Endocrinology General Hospital of Piraeus,
Piraeus, Greece. The problem of estimating parathyroid function in
CRF patients was reexamined in this study by using NcAMP determi-
nations, since such a possibility has not been previously examined in
patients with advanced CRF (GFR < 30 ml/min). We studied 63
subjects: 20 patients with CRF (group I) and 43 controls (group IL). In
all subjects NcAMP was determined, inter-alia, with a previously
described technique, both under basal conditions and at the end of 2
hours i.v. calcium infusion. Group I was further separated in subgroups
a and b according to basal plasma calcium levels. Under basal condi-
tions NcAMP (nmol/lOO ml GFR) values ( SE) were significantly (P
< 0.001) higher in group I (Ia:5.3 0.4, Lb:l6.2 5.0) than in the
control group (11:1.8 0.1). Furthermore in group Ia a statistically
significant linear correlation was observed between NcAMP and renal
function indexes (serum creatinine: r = 0.73 GFR: r = — 0.76, P <
0.001) or plasma calcium (r= —0.71 P < 0.01). During calcium infusion
NcAMP values were reduced to the normal limits in group Ia, but not
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in group lb. Findings consistent with suppressible huperparathyroid-
ism (HPT) in group Ia and non-suppressible HPT in group Ib]. These
observations—reported for the first time—suggest that in patients with
advanced CRF, accurate estimation of parathyroid function is possible
by me is of NcAMP determinations.
Significance of serum bone alkaline phosphatase ISOEnzyme in patients
with chronic renal failure (CRF). M. Siakotos, P. Singhellakis, Ev.
Constantellou, A. Pappas, S. Koulmos, S. Nikou, A. Argyropoulos, A.
Billis, Department of Endocrinology, General Hospital of Piraeus,
Piraeus, Departments of Nephrology and of Endocrinology,
"Evanghelismos" Hospital, Athens, Greece. Evaluation of serum bone
alkaline phosphatase isoenzyme determinations as index of increased
bone metabolism in patients with CRF was the purpose of the present
study, since available data on this matter are practically absent. We
studied 46 subjects: 15 patients with CRF (group I) and 31 controls
(group II). Laboratory investigation included—inter alia—determina-
tions of serum alkaline phosphatase (AP) and especially: I) total AP
(method of Bowers & McComb) and 2) bone AP isoenzyme estimated
a) indirectly (heat—inactivation method of Moss & Whitby, HI) and b)
directly by electrophoresis —E (method of Peaston et a!). Abnormally
high values (higher than the upper normal limits for age and sex) of
serum total AP and of the bone isoenzyme (measured by the HI and E
methods) were observed as follows:
Group N
Subjects with abnormal!y high serum/AP
Total
Bone
HI E
l:CRF 15 3 (20%) 14 (93%) 15 (100%)
II:Controls 31 0 0 0
It is concluded that: 1) The bone isoenzyme of the AP seems to be a
reliable index of increased bone metabolism in CRF. 2) Total serum AP
is a far less accurate index.
The desferrioxamine (DFO) infusion test in patients on regular
hemodialysis (liD). D. Memmos, A. Belechri, Z. Varghese, H.
Hatzidimitriou, M. Papadimilriou, Second Prop. Department of Inter-
nal Medicine, University of Thessaloniki and Department of Nephrol-
ogy, Royal Free Hospital, London, U.K. The DFO infusion test has
been proposed for the evaluation of aluminum (Al) overload in uremic
patients. Thirty—four patients who were on HD for 76.4 + 41.4 months
had i.v. infusion of DFO (40 mg/kg body wt) during the first 2 hours of
a dialysis session (dialysate Al < 15 rg/liter). Plasma aluminum (PAl)
was measured with atomic absorption spectrophotometry before and 4,
24 and 48 hours after the infusion of DFO. The mean + SD of PAL before
the infusion was 55.2 + 37.4 sg/liter, after 24 hours was 151.1 + 100.8
(P < 0.001) and after 48 hours it was 138.7 + 94 (P < 0.001). There was
no correlation between PAT (before DFO) and plasma calcium, phos-
phate, alkaline phosphataSe and parathyroid hormone. There was a
significant correlation between PAl 24 hours post=infusion and the
duration of dialysis treatment (P < 0.01). Bone histomorphometry (24
patients) showed that the degree of Al accumulation at the calcification
front had no correlation with PAl (before DFO), while there was no
significant correlation with PAl 24 hours after DFO infusion (P < 0.01).
In conclusion some patients on HD with "safe" PA! levels may have Al
accumulation in their hones. In contrast to PAL levels, DFO infusion is
a useful screening test for the evaluation of the Al overload of the
skeleton.
Preventive treatment with vitamin D3 to uremic patients on intermittent
hemodialysis (I.HD). S. Vafiadis, S. Karayannakis, E. Clavdianos, J.
Malamitsi, C. Kalogeropoulou, C. Koutoulidis, Department of
Nephrology and Laboratory of Nuclear Medicine, N.I.M. T.S. Hospi-
tal, Athens, Greece. The purpose of this study is the evaluation of the
preventive administration of vitamin D to uremic patients having
neither clinical nor apparent x-ray features of renal osteodystrophy
(R.O.), not having been previously treated with D3 or by
parathyreoidectomy. Twelve patients (I) of mean age 57.9 12 years,
on I.HD. for 29.6 23.8 months (ms) and presenting immunoreactive
parathormone (iPTH)=605.5 252, 7 pg/mI, alcaline phosphatase(ALP) = 129.7 88,9 IU, calcium (Ca) = 4.05 0,4 niEq/liter,
inorganic phosphorus(P) = 5.8 2.3 mg/dl and ratio of the 99"Tc-MDP
quantitative uptake of the spine, in comparison with the adjacent soft
tissues (R) = 8.03 4.1 received lcs-hydroxy = D = 12. Other patients
(LI), 59.3 15.6 years, on I.HD. for 33.4 32.9 ms and presenting
iPTH = 390 85.8 pg/mI, ALP = 69.1 20.2 lU, Ca 3.9 0.4
mEq/liter, P = 6.3 2.7 mgldl and R = 5.5 1.5 were not treated with
D3. After 4 ms, Group I showed significant (paired f-test) decrease in
iPTl-l, ALP and R (P < 0.01) and increase in Ca (P < 0.001). After 8ms
of treatment, comparisons with initial values showed decrease in iPTH
(P < 0.10), in ALP (P < 0.01), in R (P < 0.05) and increase in Ca (P <
0.01), while P did not change (P > 0.10). Group 11 showed increase in
iPTH and in ALP (P < 0.01) after 8 ms, while the rest of the values did
not change significantly. In Conclusion, with administration of D3,
biochemical and radioisotopic parameters of subclinical R.O. were
modified; apart from the well known increase in Ca, a significant
decrease of bone radioactive uptake and serum iPTU and ALP were
noticed, suggesting an amelioration of the bone metabolism, in uremic
patients on hemodialysis.
The relationship between blood pressure, electrolytes and renin—
aldosterone in essential hypertension. A. La.saridis, C. Syrganis. S.
Christodoulou, T. Georgiou, D. Grekas, S. Vaciliou, P. Nikolaidis, and
A. Tourkantonis, First Department qf Medicine, University of Thes-
saloniki, AHEPA Hospital, Thessaloniki, Greece. The purpose of the
study was to delineate the role of renin and aldosterone with regard to
sodium (Na) and potassium (K) in essential hypertension. Ninety—six
essential hypertensives, 47 males, 49 females, mean age 45.1 11.6
years, who were under no medication at least 10 days before the
admission, were included in the study after excluding secondary forms
of hypertension. Supine plasma renin activity (PRA) and plasma
aldosterone (Aldo) were measured after 4 to 5 days hospitalization and
under 150 mEg Na and 40 mEq K approximate daily intake. Systolic
(SBP) and diastolic blood pressure (DBP) was 182.6/110.0 24.6/112.8
mm Hg (X sn). PRA was 3.56 2.6 ng/ml/hr and Aldo 94.6 62.1
pg/mi. Positive relationship between SBP and age (r 0.29, P < 0.01)
and plasma urea (r = 0.24, P < 0.05) was noticed. PRA positively
correlated with Aldo (r 0.21, P < 0.05). PRA also tended to decrease
with age (r =— 0.19 P = 0.05) but aldo remained uninfluenced (r
0.07 P > 0.05). Aldo was negatively related to both plasma K (r
0.21, P < 0.05) and the urinary Na/K (r =— 0.34 P < 0.01). In
conclusion SBP in hypertensives, increases with age regardless of the
renin—aldosterone--electrolyte status. It is also related to the renal
efficiency. The renin—aldosterone axis is changed with the age. Aldo
decreases plasma K in hypertensives and it is governed by PRA and
Na/K balance.
Age related differences in natriuretic response and in GFR diurnal
variation in patients with essential hypertension, following volume expan-
sion. N. Papagalanis, N. Ritsios, J. Boutopoulos, L. Doumas, A.
Lagouranis, E. Koulouridis, N. Nicolakakis, M. Genatious, G.
Costoyianni, G. Kalycakis and V. Hatziconstantinou, Department of
Clinical Nephrology, Seventh Hospital of IKA, Athens, Greece. To
elucidate age differencies in natriuretic response following volume
expansion, we studied GFR, UN, and Uk, in 10 hypertensives and 9
normal control subjects, day (09.00 to 21.00 hours) and night (21.00 to
09.00 hours) both after 5 days strict natriopenic diet and after ECF
expansion with I liter i.v. NaCI 9% in 1 hour ECV expansion produced
an increase in BP, both systolic (P < 0.01) and diastolic (P < 0.05) only
in the older (>40) patients. GFR was higher during the day than during
the night both in patients and controls. UNa before ECV expansion
was lower during the night in both patients and controls, but this rhythm
was jnversed after ECV expansion. However the difference in the
noctural/daily UN excretion was statistically significant only for the
hypertensive patients (total patients: 83.8 9.05 mEq overnight/ 144.41
12.04 mEq day, P <0.001. Patients 40 years old: 92.95 5.65 mEq
(160.25 10.58), P < 0.05 and patients > 40 years of age 71.7 14.68
mEq (133.85 18.4 mEq, P < 0.0!). U5 was lower during the night in
the control group. On the contrary, only hypertensive patients under
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forty excreted more potassium during the night (25 7.26 mEq) than
during the day (19.8 5.87 mEq) P < 0.05. It was also established that
PRA was negatively correlated to the patients age (r =
—0.71, P <
0.05). These results indicate that old hypertensive patients do not have
any abnormality in the diurnal variation of GFR, and the increased
noctural excretion of sodium is not a characteristic feature of this age
group of patients. The different behavior of urinary potassium excretion
in young and old hypertensives reflects the different pathophysiology of
hypertension in the two age groups.
Intracellular calcium (ICCA) and the role of renin—angiotensin—aldo-
sterone before and during nitrendipine treatment in essential hyperten-
sion. A. Lasaridis, C. Syrganis, S. Christodulou, A. Tourkantonis, First
Department of Medicine, University of Thessaloniki, AHEPA Hospital,
Thessaloniki, Greece. The aim of the study was to evaluate the changes
of ICCa, the renin—aldosterone axis and the response to angiotensin II
infusion and their role in blood pressure regulation during the calcium
antagonist nitrendipine treatment. In 17 essential hypertensive patients,
mean age 42.6 10.5 years, ICCa (red blood cells) plasma renin activity(PRA) and aldosterone (Aldo) were measured before and after a 2
month and a half period of nitrendipine treatment. Angiotensin II
infusion at a rate of 1.2 and 4 ng/kg/min was also performed before and
during treatment. The systolic and diastolic blood pressure decreased
significantly (P < 0.01). ICCa also decreased from 0.649 0.270
mEq/liter to 0.365 0.225 mEq/Iiter (P < 0.05) during treatment. The
ICCa levels before treatment positively correlated with the age (r =
0.57, P < 0.05) and the diastolic blood pressure (r = 0.59 P < 0.05).
There was a slight inrease in PRA and decrease in Aldo during
treatment without reaching statistical significance. Angiotensin II infu-
sion caused a similar percent increase in blood pressure before (+ 12%)
and during (+ 12.5%) treatment. The aldo response was also
unmodified. It is possible that ICCa increases with age and that it
participates in the blood pressure regulation. Nitrendipine is an effec-
tive drug which neither stimulates renin—aldosterone axis nor changes
the sensitivity of angiotensin receptors in the arterial wall and the
adrenal cortex.
Percutaneous transluminal renal angioplasty in the therapeutic man-
agement of the renovascular hypertension—long term follow—up. C.
Za,nboulis, A. Karagiannis, S. Douma, M. Papadimitriou, P. Metaxas,
L. Kelekis, J. Artopoulos, S. Cristopoulos, Second Propedeutic De-
partment of Internal Medicine Aristotelian University of Thessaloniki,
Radiological Department of Ippokratio Hospital, Greece. During the
last three years percutaneous transluminal renal angioplasty (PTA) has
been performed in 27 patients (16 male, 11 female) with arterial
hypertension and unilateral or bilateral stenosis of the renal arteries.
Thirteen of 27 patients presented with various degrees of renal failure
(serum creatinine th:2.5 1.5 mg%) and 3 of 13 had functionally a
solitary kidney; in these patients PTA was given both for the control of
the blood pressure (BP) and also for the management of the progressive
deterioration of the renal function. Three to 36 months after the
application of PTA, 16/27 patients were normotensive without any
antihypertensive medication (AM), 10/27 presented with considerable
improvement of the control of their BP with less AM, and only in one
patient his BP remained unchanged. Renal function improved in all the
patients with renal failure (serum creatinine in: 1.7 0.8 mg%) while the
radioisotopic study with 99mTc-DTPA showed increase of the renal
blood flow in 17/27 patients. Regular radioisotopic renograms (3 to 6
months) did not provide any evidence of restenosis of the dilated renal
arteries. Conclusively renal angioplasty is a effective and safe alterna-
tive to the surgical procedure in the management of renovascular
hypertension; PTA improves renal function or inhibits its progressive
impairment; where it is not succesful it does not preclude later surgical
intervension.
The linear correlation of the measured and calculated serum osmolality
in renal failure. O.H. Stathakis, G. Kapsimalakou, C.H.R. Iatrou, J.
Boletis, A. Sachin, D. Roumeliotis, N. Zerefos, Nephrology Depart-
ment, LaIkon General Hospital Athens, Greece. In 172 individuals the
serum osmolality was measured (M 0) by cryoscopic osmometer and
calculated (C 0) by the formula: MO = 1.86 >< Na+ Urea/6 + Glyc/18.
Osmolar gap (OG) is defined as the difference between MO and CO. In
the table we record the groups of patients and the results.
Groups Pts.
Cl. Cr.
mi/mm OG
Linear correl
MO=a+bx(CO)
I. Normal 20 80—120 9.39 0.42 8.6 + l.Ox(CO)
2. ARF 20 <10 11.25 0.39 9.3 + l.Ox(CO)
3. HD 37 <5 8.65 0.26 21.0 + 0.9x(CO)
4. CRF 20 <10 15.12 0.41 95.6 + 0.7x(CO)
5. CRF 20 10—20 14.71 1.40 70.8 + 0.8X(CO)
6. CRF 20 20—30 8.98 1.40 21.5 + 0.9x(CO)
7. CRF before HD 20 <5 16.12 0.43 11.6 + l.Ox(CO)
lmnt. after HD 20 <5 9.38 0.35 16.1 + 0.9x(CO)
8. Acute on CRF 15 10—20 15.6 0.57 40.2 + 0.9x(CO)
Recovery 15 20—30 9.36 0.39 13.5 + 1.Ox(CO)
Conclusions: a) the OG in normal individuals in patients on
hemodialysis and in patients recovering from acute on CRF is similar (P
>0.1). b) In patients with ARF the OG increases (P < 0.01) c) In CRF
the OG increases very much, when clearance creatinine < 20 mI/liter (P
<0.001). d) One month after the initiation of HD OG return to normal
(P> 0.1). e) MO is in linear correlation with CO and it is expressed by
the formula: MO = a + bx(CO), for a range of values of MO for each
group.
Management of tunnel infection in CAPD patients a new technique. A.
Agrafiotis, I. Papatheofanis, A. Kostakis, S. Michael, D. Stamatiadis,
I. Homatas, Nephrology Department, Kidney Transplantation Depart-
ment, Laiko General Hospital, Athens, Greece. Failure of antibiotic
therapy in tunnel and extraperitoneal catheter's cuff infection, in CAPD
patients, led us to develop a new technique which consists in removing
and replacing the affected part of the catheter with the patient still in
CAPD. The new part of the catheter is pulled through a new tunnel with
exit site on the opposite side of the abdominal wall, while the old tunnel
is left to drain the infected area. This technique had a 100% success in
4 antibiotic resistant tunnel infection cases, and may well be used to
avoid either complete removal of the catheter or change of the method
of treatment in patients on CAPD.
Leukopenia and hypoxemia during hemodialysis, Effects of different
type of membranes and antiplatelet agent. D. Grekas, C. Syrganis, 0.
Zegla, H. Vasileri, I. Papagianis, A. Tourkantonis, First Medical
Department, University Hospital AHEPA, Thessaloniki, Greece. Six
patients, 3 male and 3 female, aged 31 to 60 years were studied. They
were on hemodialysis (HD) 4 hours thrice weekly. The study is a
comparison of six successive HD sessions on each patient, two sessions
with cuprophan membrane (CU) (Gembro 12 M), two with cellulose
acetate (CA)(C-D 3500) and two with cellulose hydrate (CH)(Secon
133). Sixty minutes prior to the first session a placebo was administered
orally, while prior to the second session 500 mg of ticlopidine.
Leucocyte and platelet counts, serum C3 complement, arterial PaO2,
PaCO2 and pH were measured before and at 15, 30, 60, 120 and 240
minutes of each HD session. At 15 mm of placebo HD session with CU
and CH a significant drop of leucocyte count (P < 0.01) was observed,
but it was less dramatic in HD with CA. This leukopenia was signifi-
cantly (P < 0.01) prevented by ticlopidine. Hypoxemia was marked in
HD placebo session with CU and CH membrans, but not with CA
membrane. This hypoxemia was prevented significantly (P < 0.01) by
ticlopidine. pH was increased within normal limits at the end of all HD
sessions, but PaCO2 showed no significant changes. C3 complement
was significantly (P < 0.01) increased during HD placebo session with
CU and CH membranes, but complement activation was prevented by
ticlopidine. It is suggested that (1) leukopenia, complement activation
and hypoxemia are less marked in HD with CA membrane than with
both CU and CH membranes (2) ticlopidine prevents the above phe-
nomena of HD membranes—blood interactions preventing probably the
platelet mediated complement activation.
Blood (B1)—dialysate (D) parallel flow (PF) in the HD filter (F) as a
means of hypotension prevention. A. Agrafiotis, J. Kyriazis, D.
Stamatiadis, J. Alexopoulos, S. Michael, E. Dafnis, Laiko General
Hospital, Nephrology Department, Athens, Greece. Fast Bi osmotic
pressure (OP) drop due to high clearance rate of micromolecular
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substances is mainly responsible for acute hypotension during HD.
"BI-D" PF could reduce hypotensive accidents by reducing the rate of
removal of those substances. Six HD patients, who had frequent
hypotensive accidents, were submitted to 'Bl-D" antiparallel flow
(APF)HD and 48 hour later to PF HD. The above procedure was
repeated twice (24 sessions). In every case, fractional urea clearance at
0 to 30, 30 to 60, 60 to 120, 120 to 240 minute periods, 4 hour creatinine
and phosphorous fractional clearance and urea drop curve divergence
for both HD modes, were evaluated. PF urea clearance was found
lower (P < 0.01) for the 30 60 minute period while BI OP was lower (P
<0.05) in APF for the 60 120 minute period. Creatinine and phospho-
rous clearances were non-significantly lower in PF. Urea drop curve
divergence was maximum at 60 minutes, APF being steeper. Linear
regression estimate showed that an —30 minutes PF HD prolongation
would equalize urea values. Eighteen hypotensive accidents and 6
muscle cramps were noted in APF and 3800 cc of n.saline were
instituted, while for PF we had 7.4 and 1100cc respectively. "Bl-D"PF,
by reducing micromolecular substances clearance rate during the initial
60 HD minutes, reduces also hypotensive accidents without HD effi-
ciency loss.
Paired filtration dialysis (P.F.D.): Two filters in series in one device. D.
Koutsikos, G. Hadjigeorgiou, V. Agrogiannis, K. Perakis, P. Ziroyan-
nis, P.M. Chezzi, Dept. of C/in. Therapeutic, University of Athens,
Greece. Hemodiafiltration which combines diffusive and convective
mass transfer provides very "adequate" clearances of small and middle
molecular weight (SMMW) toxins. The overall clearances have been
demonstrated to be always less than the sum of clearances of the
individual processes taken separately. We used a blood purification
system in which diffusion and convective transfers were kept separate
during the same session with a new single device made up of
polysulfone hemofilter (0.3 m2) assembled in series with a cuprophan
hollow—fiber dialyzer (1.1 m2). The method was clinically tested on 4
patients and for a total of 420 sessions of 3 hours duration over 11
months. The performance of the device was routinely evaluated by
calculation of the clearance for urea, creatinine, uric acid, phosphate
and vitamin Bl2. Results:QB = 300, Qut = 40.2 0.7 mI/mm duration
of PFD: 180 mm.
Substances
Urea
Creat.
Uric ac.
Phosphate
B12
218 15 58 6 5.8 1.2
191± II 55 0.98±0.7
175 10 62 9 0.48 0,15
193
87
10
7
53 12 0.47 0.14
These results confirm the original observation and constitute significant
support for the method for removal of (SMMW) toxins under normal
conditions and with significant reduction in the time required for
therapy.
The effect of malnutrition on anemia of patients on hemodialysis. Cf.
Stefanidis, fT. Papadakis, A. Patrikarea, Ch. Christodou/idou, P.N.
Ziroyannis and N.J. Papadoyannakis, Athens General Hospital, 2nd
Department of Pediatrics, Athens, Greece. There is an increasing
interest on the role of nutrition on dialysis patients. However little is
known about the effect of malnutrition on anemia. To assess this effect
protein balance, total body protein and hepatic proteinosynthesis were
compared in patients with < 3 transfusions/year (group A, N = 21) and
with > 6 transfusions/year (group B, N = 9). Patients of group A had an
hematocrit of 30.2 8.9%and of group B 20.7 l.6%(P = 0.004). No
one of our patients had a primary disease affecting anemia or nutrition.
All patients had normal values of serum iron. There was no significant
difference on age, male/female ratio, the months on hemodialysis and
serum PTH between the two groups. Energy intake (El) was estimated
from home food records. Midarm muscle circumference (MAMC) was
used to assess total body protein and serum albumin, transferrin and
pseudocholinesterase were used as indices of hepatic proteinosyn-
thesis. Comparing the two groups more patients of group B were found
to have significant lower EL <80% of the ideal (x2 = 3.9 P = 0.046),
MAMC <5th percentile (x2 = 4.9 P = 0.026), serum albumin <3.6 g/dl
(x2 = 4.8, p = 0.028), transfernn <150 mg/dl (y2:l0.5 P <0.001) and
pseudocholinesterase < 4500 lU/mI (x2:3.9 P = 0.046). These data
support the effect of malnutrition on anemia in hemodialysis patients.
The effect of I a(OH)D3 on cellular immunological status of patients on
chronic hemodlalysis. C.H. Stathakis, J. Boletis, C.H.R. Iatrou, A.
Sachin, A. Stavropoulou, D. Emmanouel, Nephrology Depertment,
Laikon General Hospital, Athens, Greece. In this study we studied the
cellular immunological status of patients on hemodialysis and the
correlation with receiving I a(OH)D3. We studied 12 normal individuals
(Group A), 12 patients on hemodialysis (HD) who received la(OH)D3
0.25 tg three times a week (Group B1) and 12 patients on HD who did
not receive la(OH)D3 (Group C). By ortho-monoclonal antibodies
(OKT3, OKT4, OKT8 T-total, T-helper and T-suppressor cells were
tested. In patients in Gr. B1 the test was repeated 4 weeks after the
discontinuation of lis(OH)D3 (Group B2). Results: (I) OKT3 in Group A
85.75 1.038% of lymphocytes, in G. B1 45.83 3.78, in Group C
59.17 5.21 and in Group B2 57.91 4.37. There was a difference
between Groups A and B1 (P < 0.001), as with Group A and Group C(P < 0.001). Group B had a difference with Group C (P < 0.05), while
no difference between Groups B2 and C (P > 0.1). (2) OKT4/OKT8 in
Group A was 2.05 0.103, in Group B, 2.05 0.368, in Group B2 1.46
0.155 and in Group C 1.65 0.155. No difference was between Group
A and Group B1 (P >0.1). There was a difference between Group A and
Group C (P < 0.05). No difference was between Groups B1 and B2 (P>
0.1). In Group B OKT4/OKT8 was greater than the ratio of Group C, but
there was no statistical significant difference (P>0.1). In Group B2 the
ratio decreased, with no statistical significant difference with the ratio of
Group C (P> 0.1). Conclusion: I a(OH)D3 suppresses T-total lympho-
cytes and increases the ratio OKT4/OKT8 in patients on HD. It must be
discontinued in patients who are to be renal transplant recipients.
The cellular immunological status of patients on hemodialysis and the
effect of la(OH)D3 and 1,25 (OH)2D3 on it. C.H. Stathakis, G. Cho/evas,
C.H.R. Iatrou, J. Boletis, S. Michael, N. Zerefos, A. Stavropou!ou,
Nephrology Department, Laikon General Hospital, Athens, Greece.
We studied the effect of la(OH)D and l,25(OH)2D3 on the lympho-
cytes of patients on hemodialysis. By orthomonoclonal antibodies
(OKT3,OKT4,OKT8) T-total, T-helper and T-suppressor cells were
tested. There were two groups of patients: Group A (N = 9) which was
receiving la(OH)D30.25 jsg/three times a week and Group B (N 7)
which did not In Group A la(OH)D3 was discontinued. Both groups
received l,25(OH)2D3 0.25 j.rg/three times a week. OKT3, OKT4, OKT8
were tested before, I and 3 weeks after the initiation of I ,25(OH)2D3.
Results: (a) in Group A there was no difference in OKT4 between
before, I and 3 weeks P> 0.1 (Wilcoxon test), while there was a great
difference in OKT8 between before and 3 weeks, P > 0.05. There was
a great difference in OKT3 between before and 3 weeks, P> 0.05. (b)
In Group B, there was no difference in OKT4 between before, 1 and 3
weeks P > 0.1 OKT8 before and 3 weeks were not analyzed. No
difference between OKT8 I and 3 weeks (P > 0.05) was found but in
graphic analysis there was an indication of difference. The was no
difference in OKT3 between before, 1 and 3 weeks (P > 0.05). (c) The
ratio OKT4/OKT8 decreased (Gr. A:2.l8 0,49—3 1.14 12 and Gr.
B:l.67 0.24 1.23 0.9). Conclusion. The patients who did not
receive a(OH)D3 had a "physical" immunosuppression of uremia
(OKT4/OKT8 1.67 0.24). The la(OH)D3 decreased T-total and
T-suppressor cells, making the ratio OKT4/OKT5 (2.18 0.49) to be as
in normal individuals (2.05 0.103). The 1 ,25(OH)2D increased T-total
and T-suppressor cells and had an immunosuppresive action, decreas-
ing OKT4IOKT8.
The significance of serum neopterin levels in renal transplantation. M.
Danii/idis, E. Alexopoulos, Z. Polymenidis, 0. Liamos, E. Sakellariou,
M. Papadimitriou, Second Prop. Department of Medicine, Aristotelian
University of Thessaloniki, Greece, Immunology and Tissue Typing
Department Hippokration Hospital of Thessaloniki, Greece. It has been
shown that an increase in the urine neopterin excretion correlated with
graft rejection. We determined the serum neopterin levels in 22 renal
graft recipients (19 from living related donors) and in 15 healthy
Clearances % Reduction
Convective mass
transfer (g)
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individuals by using a RIA method. Seventeen transplanted patients
had normal renal function at the time of study (Group I) while the
remaining had various degree of graft failure (Group 2). All patients of
group 2 had a previous history of at least 2 acute rejection episodes.
There was a significant increase of serum neopterin levels observed in
all patients of Group 2 (Mean SD) (98 55 nmol/liter) in comparison
with group 1 and the normal individuals (19 6 and 8 4 nmollliter,
respectively, P < 0.001). In conclusion, low and stable serum neopterin
levels are correleted with the absence of rejection episodes while high
levels are predictive of compromised renal function due to rejection.
Serial determination of serum neopterin levels could be an additive and
useful index for the immunological monitoring of renal graft recipients.
Experimental in situ renal preservation effect of nifedipine (NF) in the
prevention of acute renal failure (ARF). D. Grekas, S. Christodou!ou, H.
Kalekou, A. Tourkantonis, First Medical Department, University of
Thessaloniki, Greece. Calcium channel blockers have been recently
included in the group of drugs which prevent the functional defect in
some models of ARF. The aim of this study was to examine the effect
of NF during renal preservation in situ with Euro-Collins solution in 6
dogs after renal ischemia. After 60 minutes of ischemia, both arterial
clamps were removed and 300 ml of Euro-Collins solution were infused
intrarenally for 30 minutes. Collins solution for left kidney also con-
tained 10 mg of NF (NF group) and was protected from the light by
aluminum foil, while a placebo was added to the second solution
(placebo group). At the end of 2 hours after renal re-perfusion the
results are:
Parameters
Placebo
group
Nifedipine
group P
Urine volume mI/mm 0.64 0.16 1.39 0.63 <0.025
Ccreat. mI/mm 2.30 0.62 6.81 1.73 <0.005
Curea mi/mm 2.49 0.55 5.24 1.01 <0.001
FeNa% 33.00 9.88 20.00 8.88 NS
On histopathology both group of kidneys showed no significant
changes. It is suggested that nifedipine had a beneficial effect in the
prevention of ARF when it was administered during experimental renal
preservation.
Evaluation of isoenzymic changes during in situ renal ischemia with or
without renal protection. A. Giannopoulos, G. Delidis, A. Delidi, I.
Voscaki, P. Karayanakos, C. Dimopoulos, Urology clinic, University
of Athens, Laboratory of Pathological anatomy, Inst. Metaxa, Dpt of
Pathologic Physiology, University of Athens, Laboratory of Propedent-
ics chirurgical clinics, University of Athens, Athens, Greece. Three
methods of preservation of the in situ temporarily ischemic Kidney
were compared in dogs. The study was carried out in 24 dogs, divided
in 4 groups. Each group included 4 dogs in which the ischemic time was
60 minutes, and 3 dogs in which the ischemic time was 90 minutes. The
experimental animals of the first group served as controls (warm
ischaemia); in the second group renal hypothermia was accomplished
by an arterial infusion of Collins' solution at 4°C; in the third group
preservation of the kidney was attempted only by an arterial infusion of
inosine (90 to 120 mg/kg) finally in the fourth group, the infusion of
Collins' solution was combined with infusion of inosine (800-1 000mg/I
Collins solution). The assessment of the damage of the ischemic kidney
was made by histoenzymological analysis of renal tissue specimens
received from each animal just before initiation of the ischemia and on
the 21st post-operative days. The enzymes examined in this analysis
were: alkaline phosphatase, ATP-ase, glytamate dehydrogenase,
glucose-6-phosphatase, hydroxybutyrate dehydrogenase and y-GT.
These studies have shown that the ischaemic kidney is best preserved
by the arterial infusion of Collins solution with simultaneous infusion of
inosine.
The clinical significance of the determination of C-PTH (35-84PTH) and
I-PTH (1-84PTH) in chronic renal failure (CRF) and renal transplanta-
tion (RT). M. Karamouzis, M. Pyrpasopoulos, S. Kapoulas, A.
Dimitriadou—Vafiadou, A. Trakatrellis, Biochemistry Laboratory, Uni-
versity of Thessaloniki and First Medical Propedeutic Clinic, University
of Thessaloniki, Greece. We estimated the levels of I-PTH and C-V1'H
in plasma of 109 uraemic patients with various degree of renal failure, 8
successfully transplanted and 25 normal subjects. The results were the
following:
Creatinine
Groups
clearance
mI/mm I-PTH pg/mi
C-PTH
MI U/mi
1st 25 normal normal 46.7 23.3 2.76 0.64
2nd 27 uremics 91-50 62.7 37.2 3.95 1.43
3rd 33 uremics 49-20 119.8 64.0 5.52 2.04
4th 26 uremics 19.5-5 243.5 82.3 9.79 4.38
5th 23h/dialysed 0 198.2 100.9 10.60 4.30
6th 8 transplant. 45-96 107.2 61.6 4.56 1.14
The table shows that: a) The C-fragment of PTH is gradually increased
in a parallel way with the decrease of renal function. This increase
begins from the 1st stage of CRF, it is higher in the end—stage
(hemodialysis) and lower (almost normal) in the transplanted. 2) The
I-PTH is also increased gradually in the uremics. But this increase
begins at a more advanced stage of CRF, it is a little lower in the
end—stage (hemodialysis) and even lower (almost normal) in the trans-
planted. The analytical values, as well as the aforementioned values,
show that, for the secondary hyperparathyroidism in the first stage of
CRF it would be better to measure C-PTH, in the advanced and severe
uremia either C-PTH or I-PTH, and in the h/dialysis C-PTH plus I-PTH.
The influence of 1-a hydroxyvitamin D3 on uremic cataract. A.
Diamandopoulos, P. Theodoropoulos, Renal Unit, Patras State Hos-
pital, Greece. A hypocalcemic type of cataract has been reported in
dialysis patients (D.P.). It is well known that the renal failure causes
hypocalcemia due mainly to an insufficiency of active products of
vitamin D. We undertook this three year study in the hope that the
uremic cataract would be improved with the administration of vitamin
D. Three groups of patients were studied. Group A comprised 22
healthy volunteers as controls (Mean age 47.2 years). Group B com-
prised 18 D.P. (M.A. 45.8 years) who were given 150—300 mg I-a D3
annually, and group C comprised 15 D.P. (MA. 50,6 years) who were
not given vitamin D. All of them were initially examined with a slit lamp
biomicroscope for lens opacities. The D.P. of B and C groups were
reexamined after 3, 6, 12, and 24, months, and the findings were
classified on a scale from 0 to 3+. Using the paired t-test a very
significant incidence of cataract was found in the D.P. compared to
controls (P < 0.003). The incidence of cataract was continuously
decreasing in group B and increasing in group C till the difference
became statisticaly significant after 12 months. The statistical analysis
of these results is given (paired t-test). 3 month Et 2.67, Ho 2.24; 12
month Et 3.99, Ho 3.36; 6 month Et 4.89, Ho 2.01; 24 month Et 4.39, Ho
3.47. It is concluded that our D.P. had a high incidence of lens opacities
which were prevented and/or improved with vitamin D administration.
CPK heart isoenzyme (MB) in hemodialysis (HD) and CAPD patients.
A. Agrafiotis, J. Stefanou, E. Dafnis, S. Michael, G. Metaxatos, D.
Stamatiadis, Laiko General Hospital, Nephrology Department, Ath-
ens, Greece. Levels of heart CPK—isoenzyme (CPK-MB) were deter-
mined for 21 HD, 18 CAPD patients and 10 healthy controls. The
groups were selected to be homogeneous regarding sex, age and time on
dialysis (HD 12 3 months—cuprophan membrane, CAPD 10 4
months). For the CPK-MB assay biochemical method was used (Sclavo
test CPK.MB, normal levels up to 18 lU/mi). All patients had a normal
ECG at the day blood samples were drawn, and no clinical signs of
heart ischemia during the preivous 48 hours. CPK-MB levels
(mean sEM) of the HD patients were 29.2 4.4 before and 19.5 2.8
after HD (statistically insignificant difference). For the CAPD group
CPK=MB was found 18.3 1.7 with no statistically significant differ-
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ence from the HD group. Both HD & CAPD patients had CPK-MB
statistically increased levels (P < 0.01) compared to healthy controls
(2.9 0.2). For the two groups of patients total—CPK, LDH, SGOT,
SGPT, GT and amylase blood levels were normal. With the method of
assay used it was found that both HD and CAPD patients without
myocardial infarction ECG and or clinical signs of heart ischemia,
retain increased levels of the CPK heart isoenzyme. This suggests that
the isoenzyme's clearance through both peritoneum and cuprophan
membrane are low, and that its diagnostic use in clinical practice is of
limited value.
